A new study, powered by the CMTA-INC Alliance, offers answers. By analyzing data from 50 people with PMP22 variants, researchers linked specific mutations to age of onset, symptom severity, and progression—laying the groundwork for better care and trial design.
CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types
What happens when the world’s largest CMT funder joins forces with the leading clinical research network? A new era begins. Inside: the alliance changing everything.
CMTA-INC Alliance Announces 2025 Inherited Neuropathies Fellowship Recipient
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, today announced...
CMTA-INC Alliance Announces 2025 Inherited Neuropathies Fellowship Recipient: Orthopedic Surgeon to Focus on Improving Outcomes for People with CMT
The CMTA–INC Alliance announced the 2025 Inherited Neuropathies Fellowship recipient, supporting clinical research focused on corrective foot and ankle care and surgical outcomes for people with CMT.
CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types
What happens when the world’s largest CMT funder joins forces with the leading clinical research network? A new era begins. Inside: the alliance changing everything.
CMTA Board Approves $207,018 Grant to INC For Additional Clinical Trial Prep
CMTA approved a $207,018 grant to the Inherited Neuropathy Consortium (INC) to support additional clinical trial preparation work, including outcome measure and biomarker development, across multiple INC sites.
